#USA #Innovation #LabConnect #Johnson City #Advisory Board

LabConnect Announces the Launch of Its Strategic Advisory Board

LabConnect, a prominent provider of centralized laboratory services and solutions for functional service providers, has recently revealed the formation of its Strategic Advisory Board, along with the appointment of its inaugural members. This new board is poised to solidify LabConnect's standing as an industry leader globally and is designed to facilitate the company's ongoing international expansion while fostering significant investments in innovation and technology.

The primary objective of the Strategic Advisory Board is to accelerate LabConnect's mission of delivering more efficient, transparent, sustainable, and insightful solutions for its clients and partners. With a strong focus on enhancing the quality and accessibility of laboratory services, LabConnect aims to better serve the pharmaceutical and biotech industries in their quest to develop groundbreaking medications.

Key Members of the Board

Among the esteemed members joining the newly established board is Scott Evangelista, who brings over 30 years of leadership experience within the pharmaceutical sector. Currently serving as the CEO of Cairn Therapeutics, Scott's strategic insight, fundraising acumen, and stakeholder management expertise are anticipated to play a vital role in driving LabConnect's growth and innovation.

Also appointed is David Johnston, Ph.D., who possesses a robust background in scientific and operational leadership. As the former Senior Vice President and President of Clinical Research at Thermo Fisher, David led global clinical development efforts and lab services at PPD and LabCorp. His extensive knowledge in clinical development and patient recruitment is expected to elevate LabConnect's productivity while reducing clinical development costs.

Completing the trio of newly appointed board members is Patrick Hastings, a seasoned executive in operations and business development with a proven track record in the pharmaceutical and clinical laboratory sectors. As a former Global VP at Labcorp, Patrick has extensive experience in managing central laboratory services, which will significantly enhance LabConnect's operational excellence and overall business performance.

Commitment to Innovation and Community Health

Wes Wheeler, the CEO of LabConnect, expressed enthusiasm about the newest appointments to the Strategic Advisory Board, stating, “We are thrilled to welcome Scott, David, and Patrick to our board. Their combined expertise and leadership will be instrumental as LabConnect continues to innovate and expand our global footprint. This board will be pivotal in ensuring we deliver exceptional value to our customers and partners.”

Moreover, LabConnect remains committed to fostering healthier communities by assisting clients in their successful development of new medications for patients worldwide. The establishment of this Strategic Advisory Board marks an important milestone in LabConnect’s journey to reinforce its position as a renowned leader in the industry.

About LabConnect

LabConnect is recognized as the leading provider of central laboratory services, functional service provider (FSP) solutions, and scientific consulting, coupled with data integration and transformation services for complex analytical and logistical studies, including immuno-oncology, cell and gene therapies, and rare diseases. With a unique combination of cutting-edge technology, top-tier laboratories, straightforward access to key and emerging markets, and extensive expertise in specialized testing, pharmaceutical development companies can rely on LabConnect as their single source for all central laboratory services. To learn more, visit www.labconnect.com and follow us on LinkedIn.